Biblio

Author Title Type [ Year(Asc)]
Filters: Author is Mayer, Jiri  [Clear All Filters]
2024
Salmanton-García J, Marchesi F, Farina F, Weinbergerova B, Itri F, Dávila-Valls J, Martín-Pérez S, Glenthøj A, Hersby DStampe, da Silva MGomes, et al. Decoding the historical tale: COVID-19 impact on haematological malignancy patients-EPICOVIDEHA insights from 2020 to 2022. EClinicalMedicine. 2024;71:102553.
Mahon F-X, Pfirrmann M, Dulucq S, Hochhaus A, Panayiotidis P, Almeida A, Mayer J, Hjorth-Hansen H, Janssen JJWM, Mustjoki S, et al. European Stop Tyrosine Kinase Inhibitor Trial (EURO-SKI) in Chronic Myeloid Leukemia: Final Analysis and Novel Prognostic Factors for Treatment-Free Remission. J Clin Oncol. 2024:JCO2301647.
Kiladjian J-J, Marin FFerrer, Al-Ali HKathrin, Alvarez-Larran A, Beggiato E, Bieniaszewska M, Breccia M, Buxhofer-Ausch V, Cerna O, Crisan A-M, et al. ROP-ET: a prospective phase III trial investigating the efficacy and safety of ropeginterferon alfa-2b in essential thrombocythemia patients with limited treatment options. Ann Hematol. 2024.
2023
Kabut T, Weinbergerova B, Folber F, Lengerová M, Mayer J. High-dose aciclovir in CMV infection prophylaxis after allogeneic HSCT: a single-center long-term experience. Bone Marrow Transplant. 2023.
Kovacsova F, Folber F, Weinbergerova B, Stepanova R, Kabut T, Tomiska M, Krejci M, Mayer J. Low incidence of severe acute and chronic graft-versus-host disease in a long-term retrospective study with ATG Grafalon routine use. Ann Hematol. 2023.
Musto P, Salmanton-García J, Sgherza N, Bergantim R, Farina F, Glenthøj A, Seval GCengiz, Weinbergerova B, Bonuomo V, Bilgin YM, et al. Survival in multiple myeloma and SARS-COV-2 infection through the COVID-19 pandemic: Results from the epicovideha registry. Hematol Oncol. 2023.
Eckardt J-N, Röllig C, Metzeler K, Heisig P, Stasik S, Georgi J-A, Kroschinsky F, Stölzel F, Platzbecker U, Spiekermann K, et al. Unsupervised meta-clustering identifies risk clusters in acute myeloid leukemia based on clinical and genetic profiles. Commun Med (Lond). 2023;3(1):68.
2022
Drozd-Sokolowska J, Gras L, Zinger N, Zahrani MAl, Passweg J, Byrne J, Ho A, Huang X-J, Kröger N, Mayer J, et al. Allogeneic hematopoietic cell transplantation for myelodysplastic syndrome unclassifiable - a retrospective study on behalf of the Chronic Malignancies Working Party of the EBMT. Bone Marrow Transplant. 2022.
2021
Baumeister J, Maié T, Chatain N, Gan L, Weinbergerova B, de Toledo MAS, Eschweiler J, Maurer A, Mayer J, Kubesova B, et al. Early and late stage MPN patients show distinct gene expression profiles in CD34 cells. Ann Hematol. 2021.
Garderet L, Sbianchi G, Iacobelli S, Blaise D, Byrne JL, Reményi P, Apperley JF, Touzeau C, Isaksson C, Browne P, et al. Prognostic impact of early-versus-late responses to different induction regimens in patients with myeloma undergoing autologous hematopoietic cell transplantation: results from the CALM study by the CMWP of the EBMT. Eur J Haematol. 2021.
2020
Robesova B, Drncova M, Folta A, Krejci M, Folber F, Sustkova Z, Mayer J, Jeziskova I. Donor-derived DNA variability in fingernails of acute myeloid leukemia patients after allogeneic hematopoietic stem cell transplantation detected by direct PCR. Bone Marrow Transplant. 2020.
2019
Radujkovic A, Dietrich S, Blok H-J, Nagler A, Ayuk F, Finke J, Tischer J, Mayer J, Koc Y, Sorà F, et al. Allogeneic stem cell transplantation for blast crisis chronic myeloid leukemia in the era of tyrosine kinase inhibitors - A retrospective study by the EBMT Chronic Malignancies Working Party. Biol Blood Marrow Transplant. 2019.
2016
Adam Z, Pour L, Krejci M, Ševčíková S, Pourová E, Ševčíková E, Král Z, Mayer J. [Changes in the prognosis and treatment of Waldenström macroglobulinemia. Literature overview and own experience]. Vnitr Lek. 2016;62(1):25-39.
Culen M, Borsky M, Nemethova V, Razga F, Smejkal J, Jurcek T, Dvorakova D, Zackova D, Weinbergerova B, Semerad L, et al. Quantitative assessment of the CD26+ leukemic stem cell compartment in chronic myeloid leukemia: Patient-subgroups, prognostic impact, and technical aspects. Oncotarget. 2016.
2015
Robak T, Huang H, Jin J, Zhu J, Liu T, Samoilova O, Pylypenko H, Verhoef G, Siritanaratkul N, Osmanov, ii E, et al. Bortezomib-Based Therapy for Newly Diagnosed Mantle-Cell Lymphoma. N Engl J Med. 2015;372(10):944-953.
2013
Krejci M, Doubek M, Dusek J, Brychtova Y, Racil Z, Navratil M, Tomiska M, Horky O, Pospisilova S, Mayer J. Combination of fludarabine, amsacrine, and cytarabine followed by reduced-intensity conditioning and allogeneic hematopoietic stem cell transplantation in patients with high-risk acute myeloid leukemia. Ann Hematol. 2013.
Schaich M, Parmentier S, Kramer M, Illmer T, Stölzel F, Röllig C, Thiede C, Hänel M, Schäfer-Eckart K, Aulitzky W, et al. High-Dose Cytarabine Consolidation With or Without Additional Amsacrine and Mitoxantrone in Acute Myeloid Leukemia: Results of the Prospective Randomized AML2003 Trial. J Clin Oncol. 2013.